Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...
Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development
Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...
Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio
Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...
Jiangsu Hengrui Receives NMPA Approval for Adjuvant Therapy Clinical Study of Adebrelimab in NSCLC
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval...
BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy
BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120...
Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study
Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...
Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...
Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval
Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...
AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...
Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...
FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment
The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...
AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael
AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has...
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...
Immune-Onc Therapeutics’ IO-202 Earns Orphan Drug Designation for CMML from US FDA
Immune-Onc Therapeutics, the Hangzhou-based subsidiary of US company Immune-Onc Therapeutics Inc., has announced that it...
Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Zylox-Tonbridge Receives UAE Approval for Five Medical Devices, Expands Middle East Presence
Zylox-Tonbridge (HKG: 2190), a Chinese specialist in medical devices, has announced a series of product...
MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE
The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...